Status:

RECRUITING

Effect of Intensive Lipid-Lowering Therapy on Coronary Atherosclerotic Plaque Progression in Young and Middle-Aged Patients With Chronic Coronary Syndrome

Lead Sponsor:

Liu yong

Conditions:

Chronic Coronary Syndrome

Eligibility:

All Genders

18-60 years

Phase:

NA

Brief Summary

This is a multicenter, open-label, parallel-group, randomized trial to determine if intensive lipid-lowering therapy (goal for LDL-C \<1.0 mmol/L and ≥50% reduction frome baseline) could delay progres...

Detailed Description

Coronary artery disease (CAD) remains the leading cause of mortality worldwide, driven predominantly by the intricate dynamics between lipid metabolism and atherosclerosis. In recent years, the incide...

Eligibility Criteria

Inclusion

  • 1\. Aged 18-60 years at screening 2. Stable angina symptoms with suspected or confirmed coronary artery disease; 2. CCTA examination demonstrating: at least one major coronary artery with a diameter of ≥1.5mm that has not been intervened and at least one leision with 50%-70% stenosis.
  • 3\. Subjects who have been using statin therapy alone for at least 4 weeks prior to enrollment with a baseline LDL-C ≥1.8mmol/L or subjects who have not initiated lipid-lowering therapy prior to enrollment with a baseline LDL-C≥2.6mmol/L.

Exclusion

  • Left main coronary artery disease or severe three-vessel disease;
  • Ultra-high-risk ASCVD patients: ≥2 severe ASCVD events or 1 severe ASCVD event with ≥2 high-risk factors;
  • Use of PCSK9 inhibitors or ezetimibe within 8 weeks prior to study enrollment;
  • The baseline LDL-C was relatively high (LDL-C≥2.6 mmol/L in those taking statins and ≥4.9 mmol/L in those not taking statins).
  • Familial hypercholesterolemia;
  • Known allergy/intolerance to lipid-lowering drugs used in the trial;
  • Patients with severe congestive heart failure, liver or kidney dysfunction, or malignancy;
  • Pregnant or breastfeeding female patients.

Key Trial Info

Start Date :

August 12 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

March 1 2028

Estimated Enrollment :

766 Patients enrolled

Trial Details

Trial ID

NCT06896708

Start Date

August 12 2025

End Date

March 1 2028

Last Update

December 17 2025

Active Locations (7)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (7 locations)

1

The First Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, China, 400015

2

The Ninth Clinical Medical College of Guangzhou University of Chinese Medicine

Dongguan, Guangdong, China, 523000

3

The Third Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China, 510000

4

Guangdong Provincial People's Hospital

Guangzhou, Guangdong, China, 510100

Effect of Intensive Lipid-Lowering Therapy on Coronary Atherosclerotic Plaque Progression in Young and Middle-Aged Patients With Chronic Coronary Syndrome | DecenTrialz